Skip to main content
PMC home page
Tobacco Control logoLink to Tobacco Control
. 2005 Jun;14(3):161–165. doi: 10.1136/tc.2004.010272

Toward a comprehensive long term nicotine policy

N Gray 1, J Henningfield 1, N Benowitz 1, G Connolly 1, C Dresler 1, K Fagerstrom 1, M Jarvis 1, P Boyle 1
PMCID: PMC1748036  PMID: 15923465

Abstract

Global tobacco deaths are high and rising. Tobacco use is primarily driven by nicotine addiction. Overall tobacco control policy is relatively well agreed upon but a long term nicotine policy has been less well considered and requires further debate. Reaching consensus is important because a nicotine policy is integral to the target of reducing tobacco caused disease, and the contentious issues need to be resolved before the necessary political changes can be sought. A long term and comprehensive nicotine policy is proposed here. It envisages both reducing the attractiveness and addictiveness of existing tobacco based nicotine delivery systems as well as providing alternative sources of acceptable clean nicotine as competition for tobacco. Clean nicotine is defined as nicotine free enough of tobacco toxicants to pass regulatory approval. A three phase policy is proposed. The initial phase requires regulatory capture of cigarette and smoke constituents liberalising the market for clean nicotine; regulating all nicotine sources from the same agency; and research into nicotine absorption and the role of tobacco additives in this process. The second phase anticipates clean nicotine overtaking tobacco as the primary source of the drug (facilitated by use of regulatory and taxation measures); simplification of tobacco products by limitation of additives which make tobacco attractive and easier to smoke (but tobacco would still be able to provide a satisfying dose of nicotine). The third phase includes a progressive reduction in the nicotine content of cigarettes, with clean nicotine freely available to take the place of tobacco as society's main nicotine source.

Full Text

The Full Text of this article is available as a PDF (68.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashley David L., Beeson Michelle D., Johnson Diana R., McCraw Joan M., Richter Patricia, Pirkle James L., Pechacek Terry F., Song Siqing, Watson Clifford H. Tobacco-specific nitrosamines in tobacco from U.S. brand and non-U.S. brand cigarettes. Nicotine Tob Res. 2003 Jun;5(3):323–331. doi: 10.1080/1462220031000095311. [DOI] [PubMed] [Google Scholar]
  2. Ayo-Yusuf O. A., Swart T. J. P., Pickworth W. B. Nicotine delivery capabilities of smokeless tobacco products and implications for control of tobacco dependence in South Africa. Tob Control. 2004 Jun;13(2):186–189. doi: 10.1136/tc.2003.006601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Balfour D., Benowitz N., Fagerström K., Kunze M., Keil U. Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report. Eur Heart J. 2000 Mar;21(6):438–445. doi: 10.1053/euhj.1999.1949. [DOI] [PubMed] [Google Scholar]
  4. Bates C., McNeill A., Jarvis M., Gray N. The future of tobacco product regulation and labelling in Europe: implications for the forthcoming European Union directive. Tob Control. 1999 Summer;8(2):225–235. doi: 10.1136/tc.8.2.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Benowitz N. L., Henningfield J. E. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med. 1994 Jul 14;331(2):123–125. doi: 10.1056/NEJM199407143310212. [DOI] [PubMed] [Google Scholar]
  6. Djordjevic M. V., Stellman S. D., Zang E. Doses of nicotine and lung carcinogens delivered to cigarette smokers. J Natl Cancer Inst. 2000 Jan 19;92(2):106–111. doi: 10.1093/jnci/92.2.106. [DOI] [PubMed] [Google Scholar]
  7. Fant R. V., Henningfield J. E., Shiffman S., Strahs K. R., Reitberg D. P. A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav. 2000 Nov;67(3):479–482. doi: 10.1016/s0091-3057(00)00399-3. [DOI] [PubMed] [Google Scholar]
  8. Fischer S., Spiegelhalder B., Preussmann R. Tobacco-specific nitrosamines in European and USA cigarettes. Arch Geschwulstforsch. 1990;60(3):169–177. [PubMed] [Google Scholar]
  9. Foulds J., Ramstrom L., Burke M., Fagerström K. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control. 2003 Dec;12(4):349–359. doi: 10.1136/tc.12.4.349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gourlay S. G., Benowitz N. L. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther. 1997 Oct;62(4):453–463. doi: 10.1016/S0009-9236(97)90124-7. [DOI] [PubMed] [Google Scholar]
  11. Gray N., Zaridze D., Robertson C., Krivosheeva L., Sigacheva N., Boyle P. Variation within global cigarette brands in tar, nicotine, and certain nitrosamines: analytic study. Tob Control. 2000 Sep;9(3):351–351. doi: 10.1136/tc.9.3.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gray Nigel. A global approach to tobacco policy. Lung Cancer. 2003 Feb;39(2):113–117. doi: 10.1016/s0169-5002(02)00456-7. [DOI] [PubMed] [Google Scholar]
  13. Gray Nigel, Boyle Peter. The future of the nicotine-addiction market. Lancet. 2003 Sep 13;362(9387):845–846. doi: 10.1016/S0140-6736(03)14348-6. [DOI] [PubMed] [Google Scholar]
  14. Gupta Prakash C., Ray Cecily S. Smokeless tobacco and health in India and South Asia. Respirology. 2003 Dec;8(4):419–431. doi: 10.1046/j.1440-1843.2003.00507.x. [DOI] [PubMed] [Google Scholar]
  15. Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerström K. O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991 Sep;86(9):1119–1127. doi: 10.1111/j.1360-0443.1991.tb01879.x. [DOI] [PubMed] [Google Scholar]
  16. Henley S. Jane, Thun Michael J., Chao Ann, Calle Eugenia E. Association between exclusive pipe smoking and mortality from cancer and other diseases. J Natl Cancer Inst. 2004 Jun 2;96(11):853–861. doi: 10.1093/jnci/djh144. [DOI] [PubMed] [Google Scholar]
  17. Henningfield J. E., Benowitz N. L., Connolly G. N., Davis R. M., Gray N., Myers M. L., Zeller M. Reducing tobacco addiction through tobacco product regulation. Tob Control. 2004 Jun;13(2):132–135. doi: 10.1136/tc.2003.006890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Henningfield J. E., Benowitz N. L., Slade J., Houston T. P., Davis R. M., Deitchman S. D. Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tob Control. 1998 Autumn;7(3):281–293. doi: 10.1136/tc.7.3.281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Henningfield J. E., Benowitz N. L., Slade J., Houston T. P., Davis R. M., Deitchman S. D. Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tob Control. 1998 Autumn;7(3):281–293. doi: 10.1136/tc.7.3.281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Henningfield J. E., Keenan R. M. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol. 1993 Oct;61(5):743–750. doi: 10.1037//0022-006x.61.5.743. [DOI] [PubMed] [Google Scholar]
  21. Henningfield J. E., Slade J. Tobacco-dependence medications: public health and regulatory issues. Food Drug Law J. 1998;53 Suppl:75–114. [PubMed] [Google Scholar]
  22. Hurt R. D., Robertson C. R. Prying open the door to the tobacco industry's secrets about nicotine: the Minnesota Tobacco Trial. JAMA. 1998 Oct 7;280(13):1173–1181. doi: 10.1001/jama.280.13.1173. [DOI] [PubMed] [Google Scholar]
  23. Jacobs E. J., Thun M. J., Apicella L. F. Cigar smoking and death from coronary heart disease in a prospective study of US men. Arch Intern Med. 1999 Nov 8;159(20):2413–2418. doi: 10.1001/archinte.159.20.2413. [DOI] [PubMed] [Google Scholar]
  24. Jarvis M. J., Boreham R., Primatesta P., Feyerabend C., Bryant A. Nicotine yield from machine-smoked cigarettes and nicotine intakes in smokers: evidence from a representative population survey. J Natl Cancer Inst. 2001 Jan 17;93(2):134–138. doi: 10.1093/jnci/93.2.134. [DOI] [PubMed] [Google Scholar]
  25. King W., Carter S. M., Borland R., Chapman S., Gray N. The Australian tar derby: the origins and fate of a low tar harm reduction programme. Tob Control. 2003 Dec;12 (Suppl 3):iii61–iii70. doi: 10.1136/tc.12.suppl_3.iii61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Kozlowski L. T., O'Connor R. J. Cigarette filter ventilation is a defective design because of misleading taste, bigger puffs, and blocked vents. Tob Control. 2002 Mar;11 (Suppl 1):I40–I50. doi: 10.1136/tc.11.suppl_1.i40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Peto R., Lopez A. D., Boreham J., Thun M., Heath C., Jr, Doll R. Mortality from smoking worldwide. Br Med Bull. 1996 Jan;52(1):12–21. doi: 10.1093/oxfordjournals.bmb.a011519. [DOI] [PubMed] [Google Scholar]
  28. Russell M. A., Feyerabend C. Cigarette smoking: a dependence on high-nicotine boli. Drug Metab Rev. 1978;8(1):29–57. doi: 10.3109/03602537808993776. [DOI] [PubMed] [Google Scholar]
  29. Shapiro J. A., Jacobs E. J., Thun M. J. Cigar smoking in men and risk of death from tobacco-related cancers. J Natl Cancer Inst. 2000 Feb 16;92(4):333–337. doi: 10.1093/jnci/92.4.333. [DOI] [PubMed] [Google Scholar]
  30. Shiffman S., Hughes J. R., Pillitteri J. L., Burton S. L. Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample. Tob Control. 2003 Sep;12(3):310–316. doi: 10.1136/tc.12.3.310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Shiffman Saul, Waters Andrew, Hickcox Mary. The nicotine dependence syndrome scale: a multidimensional measure of nicotine dependence. Nicotine Tob Res. 2004 Apr;6(2):327–348. doi: 10.1080/1462220042000202481. [DOI] [PubMed] [Google Scholar]
  32. Slade J., Henningfield J. E. Tobacco product regulation: context and issues. Food Drug Law J. 1998;53 Suppl:43–74. [PubMed] [Google Scholar]
  33. Slade J., Henningfield J. E. Tobacco product regulation: context and issues. Food Drug Law J. 1998;53 Suppl:43–74. [PubMed] [Google Scholar]
  34. Wald N. J., Hackshaw A. K. Cigarette smoking: an epidemiological overview. Br Med Bull. 1996 Jan;52(1):3–11. doi: 10.1093/oxfordjournals.bmb.a011530. [DOI] [PubMed] [Google Scholar]
  35. Winn D. M. Smokeless tobacco and aerodigestive tract cancers: recent research directions. Adv Exp Med Biol. 1992;320:39–46. doi: 10.1007/978-1-4615-3468-6_6. [DOI] [PubMed] [Google Scholar]

Articles from Tobacco Control are provided here courtesy of BMJ Publishing Group

RESOURCES